Efficacy of Long-Term Treatment with Low-Dose Thalidomide for Patients with Relapsed / Refractory Multiple Myeloma

@inproceedings{Shimizu2012EfficacyOL,
  title={Efficacy of Long-Term Treatment with Low-Dose Thalidomide for Patients with Relapsed / Refractory Multiple Myeloma},
  author={Kazuyuki Shimizu and Hirokazu Murakami and Morio Sawamura and Yutaka Hattori and Shinichiro Okamoto and Akiyoshi Miwa and Isamu Sugiura and Chihiro Shimazaki and Masafumi Taniwaki and Tadao Ishida and Toshiaki Hayashi and Hiroshi Kosugi and Masaaki Yuge and Shinsuke Iida and Takashi Ishida and Kazutaka Sunami and Hideki Asaoku and A Tomoyo Sakai and Masahiro Abe and Toshiyuki Takagi},
  year={2012}
}
Introduction: We report the results of a prospective study of long-tern treatment with single-agent thalidomide in patients who had responded in a preceding trial of the use of thalidomide for relapsed/refractory myeloma. Patients and Methods: Nineteen patients were enrolled: 11 patients (57.9%) treated at a dosage of 100 mg/day; 2 patients (10.5%) at a… CONTINUE READING